Document Detail

The pharmacokinetics of <formula>^{124}</formula>I-rituximab in patients with rheumatoid arthritis.
MedLine Citation:
PMID:  21558619     Owner:  NLM     Status:  In-Data-Review    
Rheumatoid arthritis is a destructive inflammatory joint disorder. Pre- and mature B-cells, characterized by CD20 antigen expression, play an important role in the inflammatory process. Rituximab, a chimeric monoclonal antibody against the CD20 antigen, has been approved since 2006 for the treatment of patients with rheumatoid arthritis. However, not all patients benefit from this treatment. Persistent activity of the disease has been reported despite treatment with rituximab. Imaging of radiolabeled rituximab can be used to monitor the biodistribution of rituximab, and potentially to predict the efficacy of the treatment. In this study, rituximab was radiolabeled with <formula>^{124}</formula>Iodine for positron emission tomography (PET) imaging. The aim of this study was to investigate the pharmacokinetics and biodistribution of <formula>^{124}</formula>I-rituximab in patients with rheumatoid arthritis, to establish the optimal procedure for PET imaging. Eligible patients received 50 MBq <formula>^{124}</formula>I-rituximab, corresponding to approximately 1.5 mg rituximab. Wholebody PET/CT imaging was performed at 10 min, 24 hrs, and 48 hrs post injection. The total body activity, radioactivity in whole blood, and rituximab serum levels were determined. <formula>^{124}</formula>I-rituximab has favorable pharmacokinetics for targeting of (pathological) B cells and imaging over several days, but only after pre-treatment with unlabeled rituximab. In addition, protection of the thyroid is recommended to prevent uptake of released <formula>^{124}</formula>I.
L Tran; W V Vogel; M Sinaasappel; S Muller; J W Baars; M van Rijswijk; H J Dinant; J H Beijnen; A D R Huitema
Related Documents :
21161689 - Clinical utility of fdg-pet and pet/ct in non-malignant thoracic disorders.
2265339 - Comparison of urethral reaction to full silicone, hydrogen-coated and siliconised latex...
9253379 - Techniques for imaging bladder support.
23762349 - Design of a modular protein-based mri contrast agent for targeted application.
14743039 - Effective ultrasonographic predictor for the diagnosis of acute lobar nephronia.
16445529 - Accurate preoperative diagnosis and laparoscopic removal of the cavitated non-communica...
2544339 - Extensive extraosseous localization of bone imaging agent in a patient with renal failu...
8403769 - Pictorial review: the sonographic diagnosis of pathology in the achilles tendon.
24809669 - Spontaneous isolated posterior inferior cerebellar artery dissection: rare but underdia...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Human antibodies     Volume:  20     ISSN:  1875-869X     ISO Abbreviation:  Hum Antibodies     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2011-05-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9711270     Medline TA:  Hum Antibodies     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  7-14     Citation Subset:  IM    
Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute / Slotervaart Hospital, Amsterdam, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Antiphospholipid and other autoantibodies in a cohort of habitual aborters and healthy multiparous w...
Next Document:  Generation of novel recombinant antibodies against nitrotyrosine by antibody phage display.